샘플 요청 목록

 카트 문의
시장보고서
상품코드
1513903

세계의 낭포성 섬유증 치료제 시장

Cystic Fibrosis Therapeutics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 282 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

낭포성 섬유증 치료제 세계 시장은 2030년까지 468억 달러에 달할 전망

2023년 175억 달러로 추정되는 낭포성 섬유증 치료제 세계 시장은 2023-2030년 분석 기간 동안 15.1%의 연평균 복합 성장률(CAGR)로 성장하고 2030년에는 468억 달러에 이를 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 낭포성 섬유증 치료제는 CAGR 15.5%로 성장을 지속하고, 분석 기간 종료까지 421억 달러에 달할 것으로 예측됩니다. 낭포 성 섬유증 치료 장비 부문의 성장률은 분석 기간 동안 CAGR 13.0%로 추정됩니다.

미국 시장은 45억 달러, 중국은 CAGR 19.8%로 성장 예측

미국 낭포성 섬유증 치료제 시장은 2023년 45억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 분석 기간 2023-2030년 CAGR 19.8%로 추이했으며, 2030년에는 예측시장 규모 121억 달러에 달할 것으로 예측됩니다. 다른 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 10.0%와 12.7%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 11.3%로 성장할 것으로 예측됩니다.

낭포성 섬유증 치료제 - 주요 동향 및 촉진요인

낭포성 섬유증(CF)은 주로 호흡기계와 소화기계에 영향을 미치는 유전병으로 기도를 막고 심각한 호흡기 및 소화기계의 합병증을 일으키는 농후하고 점착성 점액의 생산이 특징입니다. 낭포 성 섬유증의 치료법은 지난 수십년동안 크게 발전하여 순수한 대증 요법에서 근본적인 유전 적 결함을 다루는 것을 목표로 한보다 적은 치료로 전환되었습니다. CF 치료제의 개발은 질병의 원인인 CFTR 유전자 돌연변이에 대한 이해의 진보에 의해 추진되어 결손 단백질의 기능을 개선하는 CFTR 조절제의 창조로 이어졌습니다. ivacaftor, lumacaftor, tezacaftor와 같은 이러한 모듈레이터는 특정 유전자 프로파일에 맞게 개인화된 의료를 제공함으로써 치료에 혁명을 일으켜 환자의 결과와 삶의 질을 크게 개선했습니다.

낭포성 섬유증의 새로운 치료법에는 새로운 항염증제, 점액 클리어런스 치료 및 유전자 치료가 포함됩니다. 항염증제는 CF 환자의 폐 장애를 일으키는 만성 염증을 억제하는 것을 목표로 합니다. 고장 식염수 및 도르나제 알파와 같은 점액 클리어런스 치료는 점액을 얇게하고 호흡기에서 점액 제거를 촉진하고 호흡 기능을 향상시킵니다. 결함이 있는 CFTR 유전자를 수정하거나 대체하는 유전자 치료는 치유의 가능성이 기대됩니다. 최근의 임상시험에서는 CRISPR/Cas9와 같은 유전자 편집기술을 통해 낭포성 섬유증의 원인이 되는 유전자 변이를 표적으로 수리할 수 있어 유망한 결과를 얻을 수 있습니다. 또한, 흡입 요법과 지질 나노입자와 같은 전달 방법의 진보는 이러한 치료의 효능과 사용 편의성을 향상시킵니다.

낭포성 섬유증 시장의 성장은 인지도와 진단률 증가, 유전자 연구의 진보, 의약품 개발에 많은 투자를 포함한 여러 요인에 의해 야기됩니다. 특히 선진국에서는 낭포성 섬유증의 유병률이 상승하고 있어 효과적인 치료에 대한 수요가 높아지고 있습니다. 신생아 스크리닝이나 유전자 검사 등의 진단 기술의 향상에 의해 이 질환의 관리에는 빠뜨릴 수 없는 조기 발견·조기 개입이 가능해지고 있습니다. 게다가 제약업계에 의한 혁신적인 치료법의 충실한 파이프라인은 관민 쌍방으로부터의 다액의 자금원조에 힘입어 새로운 치료법의 개발과 승인을 가속화하고 있습니다. 학술기관, 생명공학기업, 환자지원단체 간의 협력으로 보다 역동적이고 생산적인 연구환경이 성장하고 있습니다. 게다가 희소질환용 의약품의 지정이나 신속한 심사 등 규제상의 우대조치도 CF치료제의 개발을 뒷받침하고 있습니다. 이러한 요인들이 결합되어 낭포성 섬유증 치료제 시장이 확대되고 있으며, 이 어려운 질환에 대한 더 나은 관리와 치료법의 가능성에 기대가 되고 있습니다.

조사 대상 기업 예(총 56건)

  • AbbVie Inc.
  • Galapagos NV
  • Genentech
  • Gilead Sciences Inc.
  • Novartis AG
  • Vertex Pharmaceuticals Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

JHS 24.07.24

Global Cystic Fibrosis Therapeutics Market to Reach US$46.8 Billion by 2030

The global market for Cystic Fibrosis Therapeutics estimated at US$17.5 Billion in the year 2023, is expected to reach US$46.8 Billion by 2030, growing at a CAGR of 15.1% over the analysis period 2023-2030. Cystic Fibrosis Medication, one of the segments analyzed in the report, is expected to record a 15.5% CAGR and reach US$42.1 Billion by the end of the analysis period. Growth in the Cystic Fibrosis Treatment Devices segment is estimated at 13.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.5 Billion While China is Forecast to Grow at 19.8% CAGR

The Cystic Fibrosis Therapeutics market in the U.S. is estimated at US$4.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$12.1 Billion by the year 2030 trailing a CAGR of 19.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.0% and 12.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.3% CAGR.

Cystic Fibrosis Therapeutics - Key Trends and Drivers

Cystic fibrosis (CF) is a genetic disorder that primarily affects the respiratory and digestive systems, characterized by the production of thick, sticky mucus that can clog airways and lead to severe respiratory and gastrointestinal complications. The therapeutic landscape for cystic fibrosis has evolved significantly over the past few decades, shifting from purely symptomatic treatments to more targeted therapies aimed at addressing the underlying genetic defects. The development of CF therapeutics has been propelled by advancements in our understanding of the CFTR gene mutations that cause the disease, leading to the creation of CFTR modulators that improve the function of the defective protein. These modulators, such as ivacaftor, lumacaftor, and tezacaftor, have revolutionized treatment by offering personalized medicine approaches tailored to specific genetic profiles, significantly improving patient outcomes and quality of life.

Emerging therapies for cystic fibrosis also include novel anti-inflammatory agents, mucus clearance treatments, and gene therapies. Anti-inflammatory drugs aim to reduce the chronic inflammation that contributes to lung damage in CF patients. Mucus clearance treatments, such as hypertonic saline and dornase alfa, help thin the mucus and facilitate its removal from the airways, thus improving respiratory function. Gene therapy, which seeks to correct or replace the defective CFTR gene, holds promise for a potential cure. Recent clinical trials have shown encouraging results with gene-editing technologies like CRISPR/Cas9, which can target and repair the genetic mutations responsible for cystic fibrosis. Additionally, advancements in delivery methods, such as inhalation therapies and lipid nanoparticles, are enhancing the effectiveness and accessibility of these treatments.

The growth in the cystic fibrosis therapeutics market is driven by several factors, including increasing awareness and diagnosis rates, advancements in genetic research, and significant investments in drug development. The rising prevalence of cystic fibrosis, particularly in developed countries, has led to greater demand for effective treatments. Improved diagnostic techniques, such as newborn screening and genetic testing, are enabling earlier detection and intervention, which are crucial for managing the disease. Moreover, the pharmaceutical industry's robust pipeline of innovative therapies, supported by substantial funding from both public and private sectors, is accelerating the development and approval of new treatments. Collaboration between academic institutions, biotech companies, and patient advocacy groups is fostering a more dynamic and productive research environment. Additionally, regulatory incentives, such as orphan drug designations and expedited review processes, are encouraging the development of CF therapeutics. These factors collectively contribute to the expanding cystic fibrosis therapeutics market, offering hope for better management and potential cures for this challenging condition.

Select Competitors (Total 56 Featured) -

  • AbbVie Inc.
  • Galapagos NV
  • Genentech
  • Gilead Sciences Inc.
  • Novartis AG
  • Vertex Pharmaceuticals Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Cystic Fibrosis Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Cystic Fibrosis Spurs Growth
    • Advances in Genetic Research Propel Market Expansion
    • Improved Diagnostic Techniques Drive Early Detection and Treatment
    • Increasing Awareness Campaigns Throw the Spotlight on Cystic Fibrosis
    • Advancements in Gene Therapy Techniques Propel Growth
    • Improved Drug Delivery Methods Generate Opportunities for Enhanced Treatments
    • Newborn Screening Programs Drive Adoption of Early Intervention Strategies
    • Personalized Medicine Trends Spur Growth in Targeted Therapies
    • Chronic Inflammation Management Technologies Propel Market Expansion
    • Mucus Clearance Innovations Generate Demand for Respiratory Function Improvement
    • Technological Innovations in CRISPR/Cas9 Editing Create New Treatment Possibilities
    • Adoption of Inhalation Therapies Strengthens the Business Case for Non-Invasive Treatments
    • Economic Burden of CF Prompts Demand for Cost-Effective Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cystic Fibrosis Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cystic Fibrosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Cystic Fibrosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Medication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Medication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Medication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Treatment Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Treatment Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Treatment Methods by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospital by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • JAPAN
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • CHINA
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • EUROPE
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Cystic Fibrosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Cystic Fibrosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • FRANCE
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • GERMANY
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Cystic Fibrosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Cystic Fibrosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • INDIA
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Cystic Fibrosis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Cystic Fibrosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Cystic Fibrosis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Cystic Fibrosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030
  • AFRICA
    • Cystic Fibrosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Cystic Fibrosis Therapeutics by Treatment Method - Medication, Devices and Other Treatment Methods Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Cystic Fibrosis Therapeutics by Treatment Method - Percentage Breakdown of Value Sales for Medication, Devices and Other Treatment Methods for the Years 2014, 2024 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Cystic Fibrosis Therapeutics by Distribution Channel - Hospital, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Cystic Fibrosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital, Retail Pharmacies and Other Distribution Channels for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제